We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

DIASORIN

DiaSorin develops, produces and commercializes diagnostic tests for a wide range of clinical areas. The company’s tes... read more Featured Products: More products

Download Mobile App




Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

By LabMedica International staff writers
Posted on 18 Jul 2024
Print article
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically colonize patients, facilitating its spread within these settings. Known to be a significant risk factor for invasive infections, C. auris is associated with high mortality rates and is resistant to many antifungal medications typically used for treatment. It has been responsible for outbreaks in over 35 countries in the past decade, marking it as a critical antimicrobial resistance threat. Given this, it is crucial to screen for C. auris to enable the timely implementation of contact precautions and infection control measures that can curb its spread within healthcare facilities and prevent potential outbreaks. Traditional testing methods can take days to yield results and often require sending samples to a reference laboratory. Now, a real-time polymerase chain reaction (RT-PCR) assay for the direct in vitro qualitative detection of C. auris DNA from a swab of patients suspected of C. auris colonization delivers results in less than two hours with excellent clinical performance.

Diasorin’s (Saluggia, Italy) Simplexa C. auris Direct kit is specifically designed to quickly identify patients suspected of C. auris colonization and help prevent its spread in healthcare settings. This RT-PCR assay provides direct in vitro qualitative detection of C. auris DNA from axilla/groin swabs of patients suspected of colonization, accurately identifying the six known global clades of C. auris. Performed on the LIAISON MDX system, this kit features a user-friendly, sample-to-answer system with a streamlined workflow that delivers results in less than two hours.

The Simplexa C. auris Direct kit includes ready-to-use sample prep solution and PCR reagent for loading onto a reusable direct amplification disc on the compact LIAISON MDX system. Designed for operational simplicity, flexibility, and quality assurance for utility across any clinical lab, users can simply load samples mixed in the proprietary sample preparatory solution and reagents directly onto the disc, place the disc on the LIAISON MDX system, and press run for results in less than two hours. The test provides a comprehensive coverage across all six global C. auris clades identified across the world. The accurate and fast results can help prevent C. auris hospital outbreaks and can protect fragile patients from potentially deadly outcomes. Diasorin has received FDA De-Novo grant for the Simplexa C. auris Direct on the LIAISON MDX instrument, making it the first FDA De Novo granted PCR assay for helping to prevent C. auris infection in the healthcare setting.

"The FDA de-novo authorization for the Simplexa C. auris Direct kit fills a much-needed gap in C. auris molecular detection and uniquely positions Diasorin as the first molecular diagnostic vendor to commercialize a PCR test for the prevention and control of Candida auris infection in healthcare settings," said Angelo Rago, President of Luminex. "This de-novo molecular test is the first easy, fast, and moderate complexity assay empowering laboratories with diagnostic confidence in managing patients suspected of C. auris infection, thereby promoting better patient outcomes."

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.